Check for updates

RESEARCH ARTICLE

MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus [version 1; peer review: 3 approved]

Sandeep Chakraborty

Celia Engineers, Navi Mumbai, India

V1 First published: 03 Jun 2016, 5:1150
<https://doi.org/10.12688/f1000research.8853.1>

Latest published: 14 Sep 2016, 5:1150
<https://doi.org/10.12688/f1000research.8853.2>

Abstract

The dramatic transformation of the Zika virus (ZIKV) from a relatively unknown virus to a pathogen generating global-wide panic has exposed the dearth of detailed knowledge about this virus. Decades of research in the related Dengue virus (DENV), finally culminating in a vaccine registered for use in endemic regions (CYD-TDV), provides key insights in developing strategies for tackling ZIKV. The previously established MEPP methodology compares two conformations of the same protein and identifies residues with significant spatial and electrostatic perturbations. In the current work, MEPP analyzed the pre-and post-fusion DENV type 2 envelope (E) protein, and identified several known epitopes (His317, Tyr299, Glu26, Arg188, etc.) (MEPPitope). These residues are overwhelmingly conserved in ZIKV and all DENV serotypes. Characterization of α -helices in E-proteins show that α 1 is not conserved in the sequence space of ZIKV and DENV. Furthermore, perturbation of α 1 in the post-fusion DENV structure includes a known epitope Asp215, a residue absent in the pre-fusion α 1. A cationic β -sheet in the GAG-binding domain that is stereochemically equivalent in ZIKV and all DENV serotypes is also highlighted due to a residue pair (Arg286-Arg288) that has a significant electrostatic polarity reversal upon fusion. Finally, two highly conserved residues (Thr32 and Thr40), with little emphasis in existing literature, are found to have significant electrostatic perturbation. Thus, a combination of different computational methods enable the rapid and rational detection of critical residues that can be made the target of small drugs, or as epitopes in the search for an elusive therapy or vaccine that neutralizes multiple members of the *Flaviviridae* family.

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 14 Sep 2016			
version 1 03 Jun 2016	view	view	view

1. **Shamala Devi Sekaran**, University of Malaya, Kuala Lumpur, Malaysia
Keivan Zandi, University Malaya, Kuala Lumpur, Malaysia
2. **Raju Nagarajan**, Vanderbilt Medical Center, Nashville, USA
3. **Yi Shi**, Chinese Academy of Sciences, Beijing, China

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

Zika , Dengue , flaviviruses , microcephaly , Guillain-Barre Syndrome , envelope proteins , epitopes , neutralizing antibodies

Corresponding author: Sandeep Chakraborty (sanchak@gmail.com)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2016 Chakraborty S. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Chakraborty S. **MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus [version 1; peer review: 3 approved]** F1000Research 2016, 5:1150 <https://doi.org/10.12688/f1000research.8853.1>

First published: 03 Jun 2016, 5:1150 <https://doi.org/10.12688/f1000research.8853.1>

Introduction

The genus *Flavivirus* of the family *Flaviviridae* comprises of more than 70 viruses, including important human pathogens such as the Zika (ZIKV), Dengue (DENV), Japanese encephalitis (JEV), yellow fever (YFV), Tick-borne encephalitis (TBEV) and West Nile (WNV) viruses^{1,2}. Currently, only four flaviviruses (YFV, TBEV, JEV and DENV) have licensed vaccines^{3,4}. In flaviviruses, a single polyprotein encoded by a positive-sense RNA genome is cleaved by viral and host proteases into three structural (pre-membrane:prM, envelope:E and core:C) and seven non-structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins⁵. These Class II fusion viruses⁶ enter the cell through clathrin-mediated endocytosis^{7,8}, triggered by protonation of conserved histidine residues at low pH^{9,10}. Conformational changes of E-homodimers to E-monomers at the viral surface expose a highly conserved fusion loop¹¹, which subsequently penetrates the outer leaflet of the host membrane¹², wherein a stable trimer creates a fusion pore allowing the nucleocapsid to enter the cytosol¹³. Subsequent to viral replication, virus assembly creates nonfusogenic immature particles in the lumen of the endoplasmic reticulum. The host protease furin in the trans-Golgi network converts this non-virulent form to a smooth virulent virion by cleaving the globular prM into pr and M proteins, of which the M protein remains associated with meta-stable E homodimers^{5,14}.

Until recently, ZIKV infections were rare and confined to Asia and Africa¹⁵. An analysis of the 2007 ZIKV outbreak in Yap Island, Federated States of Micronesia concluded with the prophetic warning that ‘clinicians and public health officials should be aware of the risk of further expansion of Zika virus transmission’¹⁶. The dramatic transformation of this relatively unknown virus to a globally recognized pathogen occurred after it was detected in Brazil¹⁷, and quickly spread across the globe (Brazil, France, United States of America, and El Salvador to- date), prompting a WHO emergency committee to assess the linkage of this virus to microcephaly and Guillain-Barré syndrome (GBS)^{18,19}.

This sudden crisis has exposed the dearth of detailed knowledge about ZIKV. Computational homology modeling has been used to address this limitation exploiting the large volume of data available on related viral structures²⁰. While the genome of ZIKV was sequenced in 2007²¹, the structure of mature ZIKV²² was only recently determined, elucidating several salient features of the E and M proteins, the target of most neutralizing antibodies^{23–25}. However, decades of research on other members of the *Flavivirus* family provides a trove of information that needs to be contextualized with respect to ZIKV.

DENV has four serotypes (DENV1–4)²⁶. The essential challenge in developing a tetravalent DENV vaccine has been the fact that antibodies for a particular serotype can be enhancing, and potentially life-threatening for secondary infections with other serotypes²⁷. Apart from vaccines, other anti-viral strategies include developing peptide vaccines²⁸, using peptide-inhibitors derived from the viral proteins²⁹, inhibiting the fusion process³⁰ and anionic peptides that target cationic ‘hotspots’^{31,32}. Computational epitope predictors like the sequence based RANKpep³³ or the structure based Peptope³⁴ have been used to validate antibody binding^{35,36}. A detailed structural analysis of proteins of these flaviviruses will provide

deeper insight into conservation than a sequential analysis does. Furthermore, analyzing the spatial and electrostatic perturbations of protein structures after conformational changes arising due to the fusion process helps in identifying residues that are critical and possibly exposed to the environment, making them better candidates as vaccine epitopes or drug targets.

In the current work, several computational methods were used to analyze DENV and ZIKV E protein structures. Firstly, a quantitative analysis of spatial and electrostatic perturbation in the pre³⁷ and post-fusion¹² DENV-2 E proteins was done using MEPP³⁸. This revealed that highly perturbed residues are overwhelmingly conserved, and also epitopes of known neutralizing antibodies^{23,35,39–43}. Characterization of α -helices in E-proteins using techniques (PAGAL^{44,45}) previously applied to the Ebola virus⁴⁶, revealed that $\alpha 1$ in ZIKV-E and DENV-E proteins is not conserved in the sequence space. Furthermore, $\alpha 1$ is perturbed in the post-fusion protein in DENV2-E protein¹², and includes a known epitope that is not part of the pre-fusion $\alpha 1$ ^{41,42,47}. PAGAL analysis also highlights a cationic β -sheet within a putative GAG-binding domain^{48,49}, which consists of a pair of arginine residues that have significant electrostatic polarity reversal^{48,49}. Finally, residues that are involved in antibody neutralizing by 5J7 were re-analyzed, and some conflicting results were obtained⁵⁰.

Methods

The MEPP (version 1)³⁸ and PAGAL (version 1)⁴⁴ packages have been previously described. The recently solved cryo-EM structure of ZIKV (PDB ID:5IRE) was used as the main structure for analysis of ZIKV in the current study²². PDB ID:1OKEA was the structure of the DENV2-E protein used for analyzing domains I–III, which lacks the stem and transmembrane domains³⁷. The structure of post-fusion DENV2-E protein was obtained from PDB ID:1OK8A¹². Since the post-fusion DENV2-E protein did not have side-chains densities for residues 145–158, these residues were removed from the pre-fusion protein (PDB ID:1OKEA) in order to have an uniform comparison (see 1OKEAFIXED.pdb in [Dataset1](#)). This has the implicit assumption that this loop effects both pre-fusion and post-fusion proteins in the same manner. A radius of 6Å was used to identify interacting residues³⁸. The ‘distance perturbation index’ is computed by dividing the absolute distance deviation with the smaller of the distances.

For the stem and transmembrane domains, a DENV3 (PDB ID: 3J6SA) structure was used. Since PDB ID:3J6SA has resolution of 6Å and no side-chain atoms, SWISS-MODEL⁵¹ was used to generate the model of PDB ID:3J6SA using the ZIKV-E protein (PDB ID:5IREA) as the template (see 3J6SASWISSA.pdb in [Dataset1](#)). Hardware requirements are very modest - all results here are from a simple workstation (8GB ram) and runtimes were a few minutes at the most.

The APBS (version 1.4) parameters were set as described previously in [52](#). APBS writes out the electrostatic potential in dimensionless units of kT/e where k is Boltzmann’s constant, T is the temperature in K and e is the charge of an electron. All protein structures were rendered by PyMOL(TM) Molecular Graphics System, version 1.7.0.0. (<http://www.pymol.org/>). α -helices and β -sheets were extracted using DSSP (version 2.2.1)⁵³. Protein structures

have been superimposed using MUSTANG (mustang-3.2.1)⁵⁴. The color coding for the Edmundson wheel is as follows: all hydrophobic residues are colored red, while hydrophilic residues are colored in blue: dark blue for positively charged residues, medium blue for negatively charged residues and light blue for amides.

Multiple sequence alignment was done using MAFFT (version 7.123b)⁵⁵, and figures generated using the ENDscript server⁵⁶. In order to obtain a multiple sequence alignment with a single representative of a stereochemical group (positive, negative, aromatic and non-polar residues) the following substitutions were done: E>D, R>K, S>T, W>F, Y>F, L>M, V>M, I>M, A>M. Gly (without a side chain) and Pro (with a cyclic side chain) were not substituted. His was also not substituted, due to its importance in pH sensing among flaviviruses^{9,10}. PHYML (version 3.0) was used to generate phylogenetic trees from alignments⁵⁷.

Results

Dataset 1. Raw data for 'MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus'

<http://dx.doi.org/10.5256/f1000research.8853.d123549>

README.txt contains a description of the files.

The focus of the study in the current paper is the ZIKV and DENV envelope (E) protein, a determinant of tropism and virulence⁵⁸. Unless explicitly specified, residue numbering is based on DENV2 (PDB ID:1OKEA), while secondary structures are numbered

according to the ZIKV protein (PDB ID:5IREA). Each E-protein subunit is about 500 residues long in these flaviviruses. The soluble ectodomain has three distinct domains (I, II, III) - domain I and II are interlaced in the sequence space⁵⁹. These domains are followed by a stem region which contains two cationic amphipathic helices separated by a stretch of conserved sequences^{60,61}, ending in an anchor region with two transmembrane helices (Figure 1, Figure 2). Apart from a conserved glycosylation site (Asn153) present in all flaviviruses, DENV has an additional site for N-linked glycosylation (Asn67) which regulates interaction with the lectin DC-SIGN⁶². The hydrophobic anchoring fusion loop (residues 98-109), which penetrates the outer bilayer leaflet of the host cell membrane to initiate cell entry⁶³, is highly conserved in all flaviviruses (Figure 1, Figure 2).

Analysis of spatial and electrostatic perturbation in the post fusion DENV-E protein

The pre-(PDB ID:1OKE³⁷) and post-(PDB ID:1OK8¹²) fusion conformations of DENV2 were used for MEPP analysis³⁸. The major difference in these proteins is a 33Å displacement of domain III, as previously noted^{9,13}. Several metrics were used for identifying residues that undergo spatial, electrostatic and secondary structure perturbations. The first analysis computed pairs of residues that have an electrostatic potential difference (EPD) reversal (EPD-R) (> 150 units), were within 8 Å of each other in both conformations and had minimal distance perturbation (<4Å). Residues were marked as (i) completely conserved, (ii) stereochemically equivalent or (iii) not conserved. His317, the residue implicated in pH sensing^{64,65}, switches electrostatic polarity with respect to Thr315 (Table 1). Both His317 and Thr315 are conserved in ZIKV/DENV1-4/JEV/WNV (Figure 2), and are known epitopes^{23,43}. Another

Figure 1. The structure of the ZIKA-E protein (PDB ID:5IREA). The E-proteins form a raft-like structure, in complex with the M-proteins (not shown here). Most common exposed residues are the highly conserved fusion loop (residues 98-109 in blue), the glycosylation site (Asn154 in ZIKV, in orange), and the GAG-binding domain which consists of a cationic β -sheet (in magenta). The stem region consists of cationic amphipathic helices $\alpha 3$ and $\alpha 4$ in the E proteins in red and green, respectively. The hydrophobic transmembrane helices $\alpha 5$ and $\alpha 6$ are in cyan.

Figure 2. Multiple sequence alignment (MSA) of envelope (E) proteins from ZIKA/DENV1-4/JEV/WNV. The most prominent difference between the E protein from DENV and other viruses analyzed here is a missing stretch of amino acids near the Asn153 glycosylation site. This stretch is the possible reason for an incorrect alignment of the conserved glycosylation site (N-x-S/T) sequence in the MSA (both ClustalW and MAFFT has this issue). Also, DENV has an additional glycosylation site (Asn67) missing in other viruses. MSA was done using MAFFT⁵⁵, and the alignment of the secondary structures were done using ESPr⁵⁶.

Table 1. Residue pairs with reversal in electrostatic potential difference (EPD) in the post-fusion DENV2 E-protein. These pairs have minimal distance perturbation ($<4 \text{ \AA}$), significant reversal in EPD (> 150 units) and are within $8 \text{ \AA}$ in both conformations. For example, Arg286-Arg288, part of a cationic β -sheet and a putative GAG-binding domain, has an electrostatic perturbation without having any relative spatial displacement. F-: final value in post-fusion DENV-E protein (PDB ID:1OK8A), O-: original value in pre-fusion DENV-E protein (PDB ID:1OKEA). Conserved in ZIKV and all four DENV serotypes? - Y: yes, N: no, StCh: stereochemically equivalent. Distances in $\text{\AA}$. See Methods section for units of potential.

PDB ID:1OK8A	PDB ID:1OKEA	F-EPD	O-EPD	δ EPD	F-DIST	O-DIST	δ -DIST	Conserved
ARG/286/NH1	ARG/288/NH1	96.1	-68.5	164.6	5.6	5.7	-0.1	StCh:StCh
THR/315/OG1	HIS/317/ND1	164.6	70.6	235.2	4.1	4.6	-0.5	Y-Y
THR/40/OG1	THR/32/OG1	151.8	-134.7	286.5	5.3	7.7	-2.4	Y-Y
THR/359/OG1	SER/363/OG	104.6	-56.0	160.6	5.1	7.0	-1.9	N-N

pair (Arg286-Arg288) with EPD-R are stereochemically equivalent in ZIKV/DENV1-4/JEV/WNV (Figure 3), and lie on a putative GAG-binding domain preceding the DI/DIII linker^{48,49}. Thr359, which is an epitope for the same MAb that binds Thr315 and His317²³, but is not conserved even among DENV serotypes, is another such residue which has EPD-R with Ser363 (Figure 2). Thus, barring the pair Thr32-Thr40 (Table 1), all residues that have an EPD-R with respect to a spatially proximal residue are known to be epitopes, even when not conserved across different viruses.

Next, normalized distance deviations (see Methods) highlight Phe11, Tyr299, Ser7, Arg9, Glu26, Arg188, Glu13 and Gln316 as residues with the largest spatial perturbations (Figure 4a). Barring Ser7, all residues are completely conserved in ZIKV/DENV1-4 (Figure 2). A N-terminal peptide (DENV3,4-12 VGVGNRDFV) that enhances immunogenicity for CD8+ T cells when expressed from modified vaccinia Ankara includes Phe11, Ser7 and Arg9³⁹. Arg9 and Glu13 are also epitopes of other antibodies³⁵. This particular study also showed that the N8R substitution DNA vaccine had a more neutralizing and protective effect than wild-type immunized sera, both *in vitro* and *in vivo*³⁵. Arg9 is part of a salt bridge with Glu368 which maintains the structure of the E-protein in the pre-fusion state^{10,64}. Tyr299 is part of the epitope for the cross-reactive neutralizing MAb DENV1-E102⁶⁶. Arg188 is essential for infectivity, and is neutralized by DC4 Fab⁴⁰, while the monoclonal antibody DD18-5 recognized residue Glu26 in DENV4³⁵, a residue predicted by the Pepitope server³⁴. Thus, all spatially perturbed residues identified by MEPP are known epitopes.

The following residues have significant cumulative EPD deviations (>150 EPD units) with other residues within $6 \text{ \AA}$ - Thr32, Thr40, Lys160, Lys247, Asp249, Arg288, Met297 and His317 (Figure 4b). His317, Arg288, Thr32 and Thr40 have been discussed above. Several residues identified by this electrostatic feature do not have known references in current literature. Of these residues, Lys160 and Met297 are not conserved in ZIKV/DENV1-4, while Asp249 is conserved in DENV, but not in ZIKV (Figure 2). However, Thr32 and Thr40 are two conserved residues (Figure 2) with EPD deviations, leading to an EPD-R as described above (Table 1).

Subsequently, analysis of α -helices in the pre- and post-fusion DENV2-E protein revealed $\alpha 1$ is slightly perturbed post fusion,

increasing in length by one residue (Asp215) compared to the pre-fusion $\alpha 1$ (Figure 5, Table 2). Asp215 is important for infectivity⁴², a proven⁴¹ and predicted⁴⁷ epitope, and a membranotropic region of the E protein (peptide 29)⁶⁷.

Analysis of secondary structures

The secondary structures from DENV and ZIKV proteins were extracted using DSSP⁶³, and analyzed using PAGAL⁴⁴. The ZIKV-E protein (PDB ID:5IREA, length=501 residues) has six α -helices and thirty β -sheets (see SSEinfo.zip in Dataset 1). The Edmundson wheels⁶⁸ for these α -helices in the stem region (Table 2) shows their amphipathic cationic nature (Figure 6). Interfacial hydrophobicity plays a critical role in cell entry of viruses⁶⁹. The membranotropic $\alpha 3$ and $\alpha 4$ in DENV4⁶⁷ has been studied extensively through mutational studies of the hydrophobic face^{60,61}. Another strategy using peptide mimetic (residues 412 to 444, named DN59) derived from these helices showed inhibition of flaviviruses by releasing genomic RNA^{70,71}. A similar study based on peptide mimetic of residues 419-447 (comprising the conserved stretch following $\alpha 3$ and $\alpha 4$) inhibited viral entry⁷². These peptides were most effective at inhibition when three residues (442-444) were mutated to tryptophan, the most hydrophobic residue according to the Wimley-White whole residue hydrophobicity scale⁷³. An interesting feature of $\alpha 4$ is the complete conservation of residues on the charged surface - Ser439, Gly436, Lys432, Gly439 and H435 in DENV (Figure 6), while the hydrophobic face is much more variable. Only Asn428 is not conserved (Figure 2).

ZIKV and DENV are Class II fusion viruses that deploy β -sheet-rich domains to destabilize membranes⁶. The charged features of these β -sheets emphasizes $\beta 21$ in ZIKV (294:KCRLK, preceding domain I/III linker) as distinctive, since it has three positively charged residues (Figure 7a). Two arginine residues on this putative GAG-binding domain^{48,49}, stereochemically equivalent in ZIKV/DENV1-4/JEV/WNV (Figure 3), was identified by MEPP as having a significant electrostatic polarity reversal after membrane fusion (Table 1). This residue pair (Arg286-Arg288) remains on the β -sheet post-fusion. This cationic 'hotspot' might be the target of small anti-viral anionic peptides^{31,32}. A separate study focused on mutations in the DI/DIII linker demonstrated that a compensatory mutation in $\alpha 3$ (DENV-E Q400H) restored virus-like particle assembly disrupted by a mutation (DENV-E Y299F).

Figure 3. Multiple sequence alignment (MSA) of envelope (E) proteins from ZIKA/DENV1-4/JEV/WNV after substituting for stereochemical equivalence. The following substitutions were done in the sequence space: E>D, R>K, S>T, W>F, Y>F, L>M, V>M, I>M, A>M in order to use a single amino acid for positive, negative, aromatic and non-polar residues. Gly (without a side chain) and Pro (with a cyclic side chain) were not substituted. His was also not substituted, due to its importance in pH sensing among flaviviruses^{9,10}. These substitutions enable MAFFT to align the glycosylation site properly. Also, these show the stereochemical equivalence of the cationic residues β -21 in ZIKV (PDB ID:5IREA), which is part of the GAG-binding domain.

Figure 4. Spatial and electrostatic perturbations in the post-fusion DENV2-E protein analyzed using MEPP. MEPP analyzes the spatial and electrostatic potential difference (EPD) deviations of each residue with respect to other residues in close proximity ($< 6\text{\AA}$). **(a)** Distance deviation. Barring Ser7, all residues are completely conserved in ZIKV and DENV. All residues, barring Gln316, are known epitopes. Gln316 precedes the histidine residue responsible for initiating pH driven conformational changes during cell entry. **(b)** Electrostatic perturbation. Several residues identified by electrostatic features do not have known references as epitopes in current literature. Thr32 and Thr40 are two such residues, which are conserved in these flaviviruses.

Figure 5. Major structural differences between ZIKV and DENV E-proteins. ZIKV (PDB ID:5IREA) in cyan, DENV2 (PDB ID:1OKEA) in magenta are superimposed using MUSTANG⁵⁴. An extra loop is present in ZIKV/JEV/WNV (Figure 3), and absent in DENV, near the glycosylation site. $\alpha 1$ in ZIKV (residues 192-95) and $\alpha 1$ in DENV2 (residues 210-214) are not conserved. $\alpha 1$ of DENV2 increases in length by one post-fusion, and includes the known epitope Asp215.

Table 2. Features of α -helices in envelope (E) proteins from DENV2 and ZIKV. The soluble ectodomain has two α -helices - $\alpha 1$ and $\alpha 2$. $\alpha 1$ is perturbed in the post-fusion DENV2, increasing in length by one to include the known epitope Asp215. Moreover, $\alpha 1$ is not conserved in the sequence space of ZIKV-E. $\alpha 2$ remains conserved all E-proteins, even after fusion. $\alpha 3/\alpha 4$ are amphipathic and cationic. The transmembrane helices ($\alpha 5/\alpha 6$) with no charged residues have a low hydrophobic moment. HM: Hydrophobic moment, RPNR: Relative proportion of positive residues among charged residues, Len: length of the α -helix, NCH: number of charged residues.

PDB ID	Feature	AH	Start	End	Len	HM	RPNR	NCH
1OK8A (DENV2:post-fusion)	Asp215+	$\alpha 1$	210	215	6	2.2	0.5	2
		$\alpha 2$	257	263	7	2.1	0.5	2
1OKEA (DENV2:pre-fusion)	Asp215-	$\alpha 1$	210	214	5	1.9	1	1
		$\alpha 2$	257	263	7	2.1	0.5	2
5IREA (ZIKV:pre-fusion)	Diff from DENV2	$\alpha 1$	192	195	4	2.8	1	1
		$\alpha 2$	262	268	7	2.1	0.5	2
	amphipathic cationic	$\alpha 3$	407	423	17	10.4	0.8	5
	amphipathic cationic	$\alpha 4$	437	453	17	6	1	2
	uncharged hydrophobic	$\alpha 5$	463	477	15	2.1	-1	0
	uncharged hydrophobic	$\alpha 6$	484	498	15	1.3	-1	0

Figure 6. Edmundson wheel of the cationic amphipathic α -helices in the stem region of ZIKV-E (PDB ID:5IREA) and DENV3-E (PDB ID:3J6SA) proteins. (a) $\alpha 3$ in DENV-E protein. (b) $\alpha 3$ in ZIKV-E protein. (c) $\alpha 4$ in DENV-E protein. (d) $\alpha 4$ in ZIKV-E protein. The Edmundson wheel shows the amphipathic cationic nature of the stem helices. The hydrophobicity of residues in the hydrophobic face is an important determinant of virulence^{61,70,71}. The conservation of the charged face of $\alpha 4$ (c and d) is in contrast to several differences in the hydrophobic face. The color coding for the Edmundson wheel is as follows: all hydrophobic residues are colored red, while hydrophilic residues are colored in blue: dark blue for positively charged residues, medium blue for negatively charged residues and light blue for amides.

Figure 7. Charged profile of β -sheets in the ZIKV-E protein (PDB ID:5IREA). (a) β -21 in ZIKV-E is the most distinctive, and has three positively charged residues (290:KCRLK). The stereochemical nature of these residues are conserved in ZIKV/DENV1-4/JEV/WNV (Figure 3). (b) β 21 is part of the GAG-binding domain that precedes the domain I/III linker, and is physically proximal to the cationic α 4. This sheet has a pair (DENV:Arg286-Arg288) with electrostatic polarity reversal post-fusion. A mutation of Tyr299 to Phe299 disrupted virus-like particle assembly, although it was compensated by a mutation in α 3 (DENV-E Q400H), which is distant from Tyr299.

Interestingly, DENV-E Q400 is not conserved even among DENV serotypes⁷⁴, and Tyr299 is distant from $\alpha 3$ (Figure 7b).

Comparing E proteins in flaviviruses

The phylogenetic tree for these flaviviruses derived from the multiple sequence alignment (MSA) of the E-protein shows that TBEV and YFV are related, and distant from ZIKV/DENV1-4/JEV/WNV (see Supplementary material Figure 1). TBEV and YFV were excluded from the MSA. Excluding TBEV and YFV shows that ZIKV, JEV and WNV have a loop near the glycosylation site which is missing in DENV (Figure 2). However, both ClustalW⁷⁵ and MAFFT⁵⁵ failed to align the glycosylation residues correctly. Replacing stereochemically equivalent residues (see Methods) corrected this alignment, and also gave a better visualization of conservation and differences (Figure 3).

Conflicting data in comparison to previous studies

A recent study on the DENV3-specific human monoclonal antibody 5J7 demonstrated a very potent neutralizing effect through the binding of envelope proteins (PDB ID:3J6U)⁵⁰. Interacting residues were determined based on a distance of 8 Å since side-chain densities were not resolved (cryo-EM Fab resolution was 9 Å). Table 1 in the study reported that T35 from the heavy chain of 5J7 (PDB ID:3J6UH) interacts with four residues (Q52, Q131, E133, N134) from the DENV-E protein (PDB ID:3J6UC), and with K307 and K308 from another E-protein of the same subunit. While T35 was within 10 Å for Q52, Q131, E133 and N134, the data on K307 and K308 could not be reproduced since T35 was found to be at a much larger distance from K308 in all three subunits (see Supplementary material Figure 2). The interacting residues of the heavy chain (PDB ID:3J6UH) and the light chain (PDB ID:3J6UL) with other subunits, as computed in this study (see Supplementary material Table 1 and Supplementary material Table 2, respectively). Distance-sorted interacting residues indicates Thr51 in the DENV3-E protein (chain C) is closest to the heavy chain (H-chain) (Table 3).

Table 3. Interacting residues of the potent DENV antibody 5J7 (PDB ID:3J6U) with other subunits, sorted based on distance.

Thr51 in the DENV-3 protein (chain C) is closest to the Leu109 of the heavy chain (H-chain), and Thr223/Thr224 in the DENV-3 protein (chain C) is closest to Ile101 in the light chain (L-chain). Thr224 is conserved in ZIKV and the other DENV serotypes. However, Thr51 is conserved only in DENV1, while Thr223 is not conserved in ZIKV or other DENV serotypes, explaining the lack of neutralization of other serotypes by 5J7. The H-chain also binds to the conserved fusion loop of another DENV3-E protein (chain A).

E subunit	Antibody	E atom	Antibody atom	Distance Å
C	H-chain	THR/51/CA	LEU/109/CA	3.9
C	H-chain	THR/51/CA	GLU/108/CA	5.0
C	L-chain	THR/224/CA	ILE/101/CA	5.1
C	H-chain	THR/51/CA	LEU/110/CA	5.2
C	H-chain	GLN/52/CA	GLU/108/CA	5.3
A	H-chain	GLY/104/CA	ASN/63/CA	5.3
C	H-chain	LEU/53/CA	LEU/110/CA	5.3
A	H-chain	GLY/106/CA	SER/37/CA	5.3
A	H-chain	GLY/106/CA	VAL/61/CA	5.4
C	L-chain	THR/223/CA	TYR/100/CA	5.5

This explains the specificity of 5J7 to DENV3, since Thr51 is found only in DENV1 and DENV3. Another interacting residue, Thr223, is not conserved in any other DENV or ZIKV virus (Figure 2). A different study using only the DENV3 domain III identified K307 and K308 as binding sites for mAb 14A4-8 in DENV3, but also included other domain III residues (K325, A329, G381 and I387) not present in 5J7 binding of DENV3⁷⁶.

Limitations and conclusions

Spatial congruence of catalytic residues in the active site of functionally equivalent proteins, even with no sequence homology⁷⁷, has been long established⁷⁸. Further, electrostatic potential difference (EPD)^{79,80} was also shown to be conserved in cognate pairs of active site residues in these active sites^{82,81,82}. Comparison of apo and holo structures quantifying the spatial and electrostatic perturbations after ligand binding was shown to identify critical catalytic residues in several enzymes³⁸.

In the current work, this basic postulate was extended to posit that perturbed residues in viral envelope proteins during fusion with the host membrane are good candidates as epitopes for vaccines and small drug targets (MEPPitope). Specifically, computational methods^{38,44,53} were used to analyze spatial, electrostatic and secondary structure perturbations between a pre-³⁷ and post-fusion¹² DENV2-E protein. These residues are overwhelmingly conserved in ZIKV and all DENV serotypes (Figure 2), and are known epitopes^{23,35,39–43}. While perturbation was found to be a good predictor of an epitope, not all epitopes are perturbed. For example, the current study did not identify any residues in the fusion loop, the target of several neutralizing antibodies^{59,83–86}, or Thr51/Thr224 (Table 3) that is an epitope of a potent neutralizing antibody⁵⁰. The hydrophobic fusion loop sequence is highly conserved in all flaviviruses (Figure 2), demonstrating the importance of sequence alignment as a strategy to identify epitopes⁸⁷. The current study identified few perturbed residues in domain III (only His317 and Thr315) as significantly perturbed, consistent with the observation that although antibodies targeted to domain III endow protection and minimize enhancement when present, they are redundant and can be replaced by neutralizing antibodies targeted to other epitopes on the virion⁸⁸. This study indicates two residues (Thr32 and Thr40) as a significantly perturbed pair in terms of its electrostatic profile. Thr32 is conserved in all flaviviruses, while Thr40 is not conserved in all except TBEV, where it is the stereochemically equivalent Ser40. There has been no emphasis on these residues as epitopes in previous literature. In summary, the current study presents a computational methodology to extract structural and electrostatic features of envelope proteins that undergo conformational changes during fusion, which correlates well with known epitopes of DENV. Conservation of such residues in ZIKV provides a good strategy to leverage existing knowledge in developing ZIKV specific therapeutics.

Data availability

F1000Research: Dataset 1. Raw data for 'MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus'. README.txt contains a description of the files, [10.5256/f1000research.8853.d123549](https://doi.org/10.5256/f1000research.8853.d123549)⁸⁹

Competing interests

No competing interests were disclosed.

Grant information

The author declared that no grants were involved in supporting this work.

Acknowledgements

I gratefully acknowledge Mridul Bhattacharjee and Nitin Salaye for logistic support. I would like to thank Ravindra Makde from High Pressure and Synchrotron Radiation Physics Division, Bhabha Atomic Research Centre, Mumbai, India for discussions on DENV structures.

Supplementary material

Supplementary Figure 1. Phylogeny of different flaviviruses based on the E-protein sequence alignment. Japanese encephalitis virus (JEV, GenBank Accid:AAZ17558.1), West Nile virus (WNV, GenBank Accid: ACH99530.1), Tick-borne encephalitis virus (TBEV, GenBank Accid:AEP25269.1), Yellow fever virus (YFV, GenBank Accid:AAA92696.1). TBEV and YFV are distantly related to DENV, ZIKV, JEV and WNV.

Supplementary Table 1. Interacting residues of the heavy chain (PDB ID:3J6UH) of the potent DENV antibody 5J7 with other subunits. Interacting residues are identified as those with C α atoms within 8 Å of each other. The heavy chain binds to the A (PDB ID:3J6UA) and C (PDB ID:3J6UC) chains of the DENV-E protein, as well as the light chain (PDB ID:3J6UL).

H-chain	DENV-E Chain A	DENV-E Chain C	L-chain
T35		Q52 E133 N134	
S37	G106		
S38	G106	Q52 L53 A54 Q131	
Y39		Q52 L53	
T40		Q52	
Q50			Q107
G51			G106 Q107 G108
L52			Y94 F105 G106 Q107
E53			T104 F105
W54			P102 Y103 T104 F105
G56			P102
G57			I101 P102
P60	G106		
V61	C74 G104 C105 G106	A54	
F62	S72 R73 C74 G104 C105 G106		
N63	G104 C105		
N66			P102
Y67			P102
A68			P102
Y102			A50
D106		Q52	
K107		T51 Q52 L53 A54	
E108		T51 Q52 L53	
L109		E49 A50 T51 Q52 L53 G273 T274	
L110		A50 T51 Q52 L53 A54 K128 V130 T274	
F111		T198 N270 G273 T274	
S112			Y39 Y56 G57
R113			Y39 N41 Y56 G57 S98 Q99
A114			N41 L53 Y56 G57 S98
F115			L53
D116			L53
W118			A50 P51
G119			A50
Q120			K49 A50
G121			K49 A50

Supplementary Figure 2. Conflicting data on interacting residues of HMAb 5J7 and E-proteins (PDB ID:3J6U). Side-chain densities were not resolved for cryo-EM Fab 5J7–DENV3 map since it had a 9 Å resolution. It is reported that ‘a slightly negatively charged patch formed by T35, S37, S82 and S84 of the heavy chain interacted with a positively charged patch formed by K307 and K308 of the E protein’, by considering interacting residues between Fab and E proteins where pairs of $C\alpha$ atoms are < 8 Å. However, the $C\alpha$ atoms of these residues are quite far. For example, T35 from 5J7 is 108, 51 and 78 Å away from K308 in the three E-proteins (PDB ID:3J6UA, 3J6UC and 3J6UE), respectively.

Supplementary Table 2. Interacting residues of the light chain (PDB ID:3J6UL) of the potent DENV antibody 5J7 with other subunits. The $C\alpha$ atoms of interacting residues are within 8 Å of each other. The C-chain of the DENV-E protein interacts with both the heavy and light chains.

L-chain	DENV-E Chain C (3J6UC)	H-chain (3J6UH)
D8	E225	
S35	E123	
S37	E123	
Y39		S112 R113
N41		R113 A114
K49		Q120 G121
A50		Y102 W118 G119 Q120 G121
P51		W118
L53		A114 F115 D116
Y56		S112 R113 A114
G57		S112 R113 A114
S60	S271 G273	
Y94		L52
S98		R113 A114
Q99		R113
Y100	T223 T224 E225	
I101	A222 T223 T224 E225	G57
P102	T224 E225	W54 G56 G57 N66 Y67 A68
Y103		W54
T104		E53 W54
F105		L52 E53 W54
G106		G51 L52
Q107		Q50 G51 L52
G108		G51

References

1. Kuno G, Chang GJ, Tsuchiya KR, *et al.*: **Phylogeny of the genus *Flavivirus***. *J Virol*. 1998; 72(1): 73–83.
[PubMed Abstract](#) | [Free Full Text](#)
2. Mukhopadhyay S, Kuhn RJ, Rossmann MG: **A structural perspective of the *flavivirus* life cycle**. *Nat Rev Microbiol*. 2005; 3(1): 13–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Guy B, Briand O, Lang J, *et al.*: **Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward**. *Vaccine*. 2015; 33(50): 7100–7111.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Shan C, Xie X, Barrett AD, *et al.*: **Zika virus: Diagnosis, therapeutics, and vaccine**. *ACS Infect Dis*. 2016; 2(3): 170–172.
[Publisher Full Text](#)
5. Perera R, Kuhn RJ: **Structural proteomics of dengue virus**. *Curr Opin Microbiol*. 2008; 11(4): 369–377.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. White JM, Delos SE, Brecher M, *et al.*: **Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme**. *Crit Rev Biochem Mol Biol*. 2008; 43(3): 189–219.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. van der Schaar HM, Rust MJ, Chen C, *et al.*: **Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells**. *PLoS Pathog*. 2008; 4(12): e1000244.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Smit JM, Moesker B, Rodenhuis-Zybert I, *et al.*: **Flavivirus cell entry and membrane fusion**. *Viruses*. 2011; 3(2): 160–171.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Mueller DS, Kampmann T, Yennamalli R, *et al.*: **Histidine protonation and the activation of viral fusion proteins**. *Biochem Soc Trans*. 2008; 36(Pt 1): 43–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Kampmann T, Mueller DS, Mark AE, *et al.*: **The role of histidine residues in low-pH-mediated viral membrane fusion**. *Structure*. 2006; 14(10): 1481–1487.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Rockstroh A, Barzon L, Pacenti M, *et al.*: **Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections**. *PLoS Negl Trop Dis*. 2015; 9(11): e0004218.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Modis Y, Ogata S, Clements D, *et al.*: **Structure of the dengue virus envelope protein after membrane fusion**. *Nature*. 2004; 427(6972): 313–319.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Bressanelli S, Stiasny K, Allison SL, *et al.*: **Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation**. *EMBO J*. 2004; 23(4): 728–738.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Yu IM, Zhang W, Holdaway HA, *et al.*: **Structure of the immature dengue virus at low pH primes proteolytic maturation**. *Science*. 2008; 319(5871): 1834–1837.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Hayes EB: **Zika virus outside Africa**. *Emerg Infect Dis*. 2009; 15(9): 1347–1350.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Duffy MR, Chen TH, Hancock WT, *et al.*: **Zika virus outbreak on Yap Island, Federated States of Micronesia**. *N Engl J Med*. 2009; 360(24): 2536–2543.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Zanluca C, Melo VC, Mosimann AL, *et al.*: **First report of autochthonous transmission of Zika virus in Brazil**. *Mem Inst Oswaldo Cruz*. 2015; 110(4): 569–572.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Cao-Lormeau VM, Blake A, Mons S, *et al.*: **Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study**. *Lancet*. 2016; 387(10027): 1531–1539.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Smith DW, Mackenzie J: **Zika virus and Guillain-Barré syndrome: another viral cause to add to the list**. *Lancet*. 2016; 387(10027): 1486–1488.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Ekins S, Liebler J, Neves BJ, *et al.*: **Illustrating and homology modeling the proteins of the Zika virus [version 1; referees: 1 approved with reservations]**. *F1000Res*. 2016; 5: 275.
[Publisher Full Text](#)
21. Kuno G, Chang GJ: **Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses**. *Arch Virol*. 2007; 152(4): 687–696.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Sirohi D, Chen Z, Sun L, *et al.*: **The 3.8 Å resolution cryo-em structure of Zika virus**. *Science*. 2016; 352(6284): 467–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Sukupolvi-Petty S, Austin SK, Purtha WE, *et al.*: **Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes**. *J Virol*. 2007; 81(23): 12816–12826.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Messer WB, de Alwis R, Yount BL, *et al.*: **Dengue virus envelope protein domain III hinge determines long-lived serotype-specific dengue immunity**. *Proc Natl Acad Sci U S A*. 2014; 111(5): 1939–1944.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Falconar AK: **Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins**. *Arch Virol*. 1999; 144(12): 2313–2330.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Yacoub S, Mongkolsapaya J, Screaton G: **Recent advances in understanding dengue [version 1; referees: 3 approved]**. *F1000Res*. 2016; 5: pii: F1000 Faculty Rev-78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Guzman MG, Vazquez S: **The complexity of antibody-dependent enhancement of dengue virus infection**. *Viruses*. 2010; 2(12): 2649–2662.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Li W, Joshi MD, Singhania S, *et al.*: **Peptide Vaccine: Progress and Challenges**. *Vaccines (Basel)*. 2014; 2(3): 515–536.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Schmidt AG, Yang PL, Harrison SC: **Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate**. *PLoS Pathog*. 2010; 6(4): e1000851.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. De La Guardia C, Leonart R: **Progress in the identification of dengue virus entry/fusion inhibitors**. *Biomed Res Int*. 2014; 2014: 825039.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Laosuthipong C, Kanthong N, Fiegel TW: **Novel, anionic, antiviral septapeptides from mosquito cells also protect monkey cells against dengue virus**. *Antiviral Res*. 2013; 98(3): 449–456.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Alhoot MA, Rathinam AK, Wang SM, *et al.*: **Inhibition of dengue virus entry into target cells using synthetic antiviral peptides**. *Int J Med Sci*. 2013; 10(6): 719–729.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Reche PA, Glutting JP, Zhang H, *et al.*: **Enhancement to the rankpep resource for the prediction of peptide binding to MHC molecules using profiles**. *Immunogenetics*. 2004; 56(6): 405–419.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Mayrose I, Penn O, Erez E, *et al.*: **Pepitope: epitope mapping from affinity-selected peptides**. *Bioinformatics*. 2007; 23(23): 3244–3246.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Tang CT, Liao MY, Chiu CY, *et al.*: **Generation of Monoclonal Antibodies Against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein**. *PLoS One*. 2015; 10(8): e0136328.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Wen JS, Jiang LF, Zhou JM, *et al.*: **Computational prediction and identification of dengue virus-specific CD4⁺ T-cell epitopes**. *Virus Res*. 2008; 132(1–2): 42–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Modis Y, Ogata S, Clements D, *et al.*: **A ligand-binding pocket in the dengue virus envelope glycoprotein**. *Proc Natl Acad Sci U S A*. 2003; 100(12): 6986–6991.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Chakraborty S: **A quantitative measure of electrostatic perturbation in holo and apo enzymes induced by structural changes**. *PLoS One*. 2013; 8(3): e59352.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Quinan BR, Flesch IE, Pinho TM, *et al.*: **An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8⁺ T cells and antibody when expressed from modified vaccinia ankara**. *Vaccine*. 2014; 32(25): 2972–2979.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Cox K, Tang A, Chen Z, *et al.*: **Isolation of dengue neutralizing antibodies from single cell sorted human antigen specific memory b cell cultures (vac11p.1107)**. *J Immunol*. 2015; 194(1 Supplement): 212–15.
[Reference Source](#)
41. Lin HE, Tsai WY, Liu IJ, *et al.*: **Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay**. *PLoS Negl Trop Dis*. 2012; 6(1): e1447.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Kroschewski H, Sagripanti JL, Davidson AD: **Identification of amino acids in the dengue virus type 2 envelope glycoprotein critical to virus infectivity**. *J Gen Virol*. 2009; 90(Pt 10): 2457–2461.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Midgley CM, Flanagan A, Tran HB, *et al.*: **Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity**. *J Immunol*. 2012; 188(10): 4971–4979.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Chakraborty S, Rao B, Dandekar A: **PAGAL - Properties and corresponding graphics of alpha helical structures in proteins [version 2; referees: 2 approved]**. *F1000Res*. 2014; 3: 206.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Chakraborty S, Phu M, de Moraes TP, *et al.*: **The PDB database is a rich source of alpha-helical anti-microbial peptides to combat disease causing pathogens [version 2; referees: 2 approved, 1 approved with reservations]**. *F1000Res*. 2014; 3: 295.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Chakraborty S, Rao B, Asgerirsson B, *et al.*: **Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of**

- alpha-helix mediated protein-protein interactions [version 3; referees: 2 approved]. *F1000Res*. 2014; 3: 251.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Mazumder R, Hu ZZ, Vinayaka CR, *et al.*: Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. *Virus Genes*. 2007; 35(2): 175–186.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Chen Y, Maguire T, Hileman RE, *et al.*: Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. *Nat Med*. 1997; 3(8): 866–871.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Roehrig JT, Butrapet S, Liss NM, *et al.*: Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion. *Virology*. 2013; 441(2): 114–125.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Fibriansah G, Tan JL, Smith SA, *et al.*: A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. *Nat Commun*. 2015; 6: 6341.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Arnold K, Bordoli L, Kopp J, *et al.*: The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinformatics*. 2006; 22(2): 195–201.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Chakraborty S, Minda R, Salaye L, *et al.*: Active site detection by spatial conformity and electrostatic analysis—unravelling a proteolytic function in shrimp alkaline phosphatase. *PLoS One*. 2011; 6(12): e28470.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Joosten RP, te Beek TA, Krieger E, *et al.*: A series of PDB related databases for everyday needs. *Nucleic Acids Res*. 2011; 39(Database issue): D411–419.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Konagurthu AS, Whisstock JC, Stuckey PJ, *et al.*: MUSTANG: a multiple structural alignment algorithm. *Proteins*. 2006; 64(3): 559–574.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Katoh K, Standley DM: MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol*. 2013; 30(4): 772–780.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Robert X, Gouet P: Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res*. 2014; 42(Web Server issue): W320–W324.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Guindon S, Lethiec F, Duroux P, *et al.*: PHYML Online—a web server for fast maximum likelihood-based phylogenetic inference. *Nucleic Acids Res*. 2005; 33(Web Server issue): W557–559.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Wan SW, Lin CF, Wang S, *et al.*: Current progress in dengue vaccines. *J Biomed Sci*. 2013; 20(37): 2–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Dejnirattisai W, Wongwiwat W, Supasa S, *et al.*: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. *Nat Immunol*. 2015; 16(2): 170–177.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Lin SR, Zou G, Hsieh SC, *et al.*: The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry. *J Virol*. 2011; 85(10): 5159–5171.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Purdy DE, Chang GJ: Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. *Virology*. 2005; 333(2): 239–250.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Mondotte JA, Lozach PY, Amara A, *et al.*: Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. *J Virol*. 2007; 81(13): 7136–7148.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Nayak V, Dessau M, Kucera K, *et al.*: Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. *J Virol*. 2009; 83(9): 4338–4344.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Prakash MK, Barducci A, Parrinello M: Probing the mechanism of pH-induced large-scale conformational changes in dengue virus envelope protein using atomistic simulations. *Biophys J*. 2010; 99(2): 588–594.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Chaudhury S, Ripoll DR, Wallqvist A: Structure-based pKa prediction provides a thermodynamic basis for the role of histidines in pH-induced conformational transitions in dengue virus. *Biochem Biophys Res*. 2015; 4: 375–385.
[Publisher Full Text](#)
 66. Shrestha B, Brien JD, Sukupolvi-Petty S, *et al.*: The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. *PLoS Pathog*. 2010; 6(4): e1000823.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Nemésio H, Palomares-Jerez F, Villalain J: The membrane-active regions of the dengue virus proteins C and E. *Biochim Biophys Acta*. 2011; 1808(10): 2390–2402.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Schiffer M, Edmundson AB: Use of helical wheels to represent the structures of proteins and to identify segments with helical potential. *Biophys J*. 1967; 7(2): 121–135.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Badani H, Garry RF, Wimley WC: Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. *Biochim Biophys Acta*. 2014; 1838(9): 2180–2197.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Lok SM, Costin JM, Hrobowski YM, *et al.*: Release of dengue virus genome induced by a peptide inhibitor. *PLoS One*. 2012; 7(11): e50995.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Hrobowski YM, Garry RF, Michael SF: Peptide inhibitors of dengue virus and West Nile virus infectivity. *Viol J*. 2005; 2(1): 49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. Schmidt AG, Yang PL, Harrison SC: Peptide inhibitors of flavivirus entry derived from the E protein stem. *J Virol*. 2010; 84(24): 12549–12554.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. White SH, Wimley WC: Membrane protein folding and stability: physical principles. *Annu Rev Biophys Biomol Struct*. 1999; 28(1): 319–365.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. de Wispelaere M, Yang PL: Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly. *J Virol*. 2012; 86(13): 7072–7083.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 75. Larkin MA, Blackshields G, Brown NP, *et al.*: Clustal W and Clustal X version 2.0. *Bioinformatics*. 2007; 23(21): 2947–2948.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Matsui K, Gromowski GD, Li L, *et al.*: Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. *J Gen Virol*. 2010; 91(Pt 9): 2249–2253.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Rawlings ND, Barrett AJ: Evolutionary families of peptidases. *Biochem J*. 1993; 290(Pt 1): 205–218.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. Kleywegt GJ: Recognition of spatial motifs in protein structures. *J Mol Biol*. 1999; 285(4): 1887–1897.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Baker NA, Sept D, Joseph S, *et al.*: Electrostatics of nanosystems: application to microtubules and the ribosome. *Proc Natl Acad Sci USA*. 2001; 98(18): 10037–10041.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Dolinsky TJ, Nielsen JE, McCammon JA, *et al.*: PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. *Nucleic Acids Res*. 2004; 32(Web Server issue): W665–667.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 81. Chakraborty S, Rao BJ: A measure of the promiscuity of proteins and characteristics of residues in the vicinity of the catalytic site that regulate promiscuity. *PLoS One*. 2012; 7(2): e32011.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 82. Chakraborty S, Asgerirsson B, Minda R, *et al.*: Inhibition of a cold-active alkaline phosphatase by imipenem revealed by *in silico* modeling of metallo- β -lactamase active sites. *FEBS Lett*. 2012; 586(20): 3710–3715.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Smith SA, de Alwis AR, Kose N, *et al.*: The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1c19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. *MBio*. 2013; 4(6): e00873–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Lai CY, Tsai WY, Lin SR, *et al.*: Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. *J Virol*. 2008; 82(13): 6631–6643.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Cox KS, Tang A, Chen Z, *et al.*: Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures. In *mAbs*. number just-accepted, Taylor & Francis, 2016; 8(1): 129–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Deng YQ, Dai JX, Ji GH, *et al.*: A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. *PLoS One*. 2011; 6(1): e16059.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. Leng CH, Liu SJ, Tsai JP, *et al.*: A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. *Microbes Infect*. 2009; 11(2): 288–295.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Williams KL, Wahala WM, Orozco S, *et al.*: Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement *in vivo*. *Virology*. 2012; 429(1): 12–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 89. Chakraborty S: Dataset 1 in: MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus. *F1000Research*. 2016.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 29 July 2016

<https://doi.org/10.5256/f1000research.9528.r15317>

© 2016 Shi Y. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Yi Shi

Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

In the manuscript entitled "MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus", Sandeep Chakraborty analyzed the pre- and post-fusion DENV type 2 envelope (E) protein, and identified several known epitopes, which are conserved in ZIKV and all DENV serotypes. Perturbations of spatial and electrostatic or secondary structure identified by a combination of different computational methods help to detect critical residues that can be made target of therapies.

Overall, the paper provides interesting data. The paper could be improved by addressing the following points:

1. The title is too long and needs to be shortened.
2. There are some new antibodies against ZIKV or DENV reported recently, the paper would benefit by adding new information.
3. α 5 and 6 are not labeled in Figure 1.
4. In the section of "conflicting data in comparison to previous studies" line 9, the statement "... from another E-protein of the same subunit" is inaccurate as subunit refers to a single polypeptide chain.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 08 Sep 2016

Sandeep Chakraborty, Celia Engineers, Navi Mumbai, India

Dear Dr Shi,

I would like to thank you for taking the time to review this paper, and providing constructive criticism on the overall manuscript. I have revised the manuscript based on the comment of all three reviewers.

Please find my responses below.

In the manuscript entitled " MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus", Sandeep Chakraborty analyzed the pre- and post-fusion DENV type 2 envelope (E) protein, and identified several known epitopes, which are conserved in ZIKV and all DENV serotypes. Perturbations of spatial and electrostatic or secondary structure identified by a combination of different computational methods help to detect critical residues that can be made target of therapies.

Overall, the paper provides interesting data. The paper could be improved by addressing the following points:

The title is too long and needs to be shortened.

>> Done.

There are some new antibodies against ZIKV or DENV reported recently, the paper would benefit by adding new information.

>> Ref 79 and 88 have been added.

α 5 and 6 are not labeled in Figure 1.

>> Done.

In the section of "conflicting data in comparison to previous studies" line 9, the statement "... from another E-protein of the same subunit" is inaccurate as subunit refers to a single polypeptide chain.

>> The word "subunit" has been replaced with "complex".

I would like to thank you once again for the positive comments.

best wishes,

Sandeep

Competing Interests: No competing interests were disclosed.

Reviewer Report 28 July 2016

<https://doi.org/10.5256/f1000research.9528.r15004>

© 2016 Nagarajan R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Raju Nagarajan

Vanderbilt Vaccine Center, Vanderbilt Medical Center, Nashville, TN, USA

The author performed an essential structural analysis of ZIKV and DENV envelope proteins and reported the identification of unreported epitope residues with conservation details. The quality of writing and analysis is acceptable with some minor corrections.

1. The text is not much visible in Figure 6 and has to be revised.
2. In the caption of figure 5, it should be "192-195" instead of "192-95".
3. Title should be shortened.
4. The first sentence in the "Analysis of secondary structures" has to be revised to ensure that the analysis only performed for envelope proteins.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 08 Sep 2016

Sandeep Chakraborty, Celia Engineers, Navi Mumbai, India

Dear Dr Nagarajan,

I would like to thank you for taking the time to review this paper, and providing constructive criticism on the overall manuscript. I have revised the manuscript based on the comment of all three reviewers.
Please find my responses below.

The author performed an essential structural analysis of ZIKV and DENV envelope proteins and reported the identification of unreported epitope residues with

conservation details. The quality of writing and analysis is acceptable with some minor corrections.

The text is not much visible in Figure 6 and has to be revised.

>> This figure is high resolution, and text is visible clearly. I will request the typesetting to increase the size of this figure in the pdf.

In the caption of figure 5, it should be "192-195" instead of "192-95".

>> Done.

Title should be shortened.

>> Done.

The first sentence in the "Analysis of secondary structures" has to be revised to ensure that the analysis only performed for envelope proteins.

>> Done.

I would like to thank you once again for the positive comments.
best wishes,
Sandeep

Competing Interests: No competing interests were disclosed.

Reviewer Report 15 June 2016

<https://doi.org/10.5256/f1000research.9528.r14191>

© 2016 Sekaran S et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Shamala Devi Sekaran

Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Keivan Zandi

Department Of Medical Microbiology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia

1. The title needs to be shortened and revised as the should reflect the nature of the work which is all computational
2. Some other minor comments

- a. vaccine is only registered to date in 3 countries and not used by endemic regions as stated in line 4 of the abstract - please rewrite this.
- b. The last sentence has to be revised as I am not sure this addresses targets for drugs
- c. The last paragraph of introduction - was quantitative analysis of Den-2 E done with MEPP?
- d. Please check citation of APBS (version 1.4) which is given as Ref 52
- e. In the analysis of secondary structures - first sentence needs to revise as this was only done for the E protein and not all proteins

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 08 Sep 2016

Sandeep Chakraborty, Celia Engineers, Navi Mumbai, India

Dear Dr Sekaran and Dr Zandi,

I would like to thank you for taking the time to review this paper, and providing constructive criticism on the overall manuscript. I have revised the manuscript based on the comment of all three reviewers.

Please find my responses below.

The title needs to be shortened and revised as the should reflect the nature of the work which is all computational

>> Done.

Some other minor comments

a. vaccine is only registered to date in 3 countries and not used by endemic regions as stated in line 4 of the abstract - please rewrite this.

>> Done

b. The last sentence has to be revised as I am not sure this addresses targets for drugs

>> Revised. I have made the changes in the main manuscript too.

c. The last paragraph of introduction - was quantitative analysis of Den-2 E done with MEPP?

>> Yes.

d. Please check citation of APBS (version 1.4) which is given as Ref 52

>> Ref 52 was intended to direct the reader to the parameters used. I have cited APBS before this reference to remove the confusion.

e. In the analysis of secondary structures - first sentence needs to revise as this was only done for the E protein and not all proteins

>> Fixed.

I would like to thank you once again for the positive comments.

best wishes,
Sandeep

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research